NanoString Acquisition FAQ

When will NanoString become part of Bruker Corporation?

We expect the sale transaction to be completed and closed in May.

How are your organizations synergistic?

Bruker is a leading global provider of high-performance scientific instruments and diagnostic solutions. Like NanoString, Bruker has deep experience in enabling customers to explore biology at the microscopic, molecular and cellular levels. Bruker’s CellScape™ spatial proteomics platform offered by its Canopy Biosciences business unit is complementary to NanoString’s spatial biology platforms. Bruker and NanoString share a passion for creating innovation and putting it in the hands of customers for the advancement of human health.

Does this agreement enable NanoString to end its chapter 11 restructuring?

Yes. Following the closing of the transaction with Bruker, NanoString’s business operations will no longer be the subject of a chapter 11 proceeding and will be owned by Bruker on a go-forward basis.

What can customers expect from NanoString once the acquisition is complete?

Continuity and ongoing availability of NanoString’s products and services.